Company Overview of BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trials for ischemic systolic heart failure. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. The company is also developing CardiALLO Cell Therapy System, an allogeneic off the shelf mesenchymal stem cell product candidate, which is in Phase II trials used for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system and Morph ...
125 Shoreway Road
San Carlos, CA 94070
Key Executives for BioCardia, Inc.
President, CEO & Director
Total Annual Compensation: $357.6K
Vice President of Finance
Total Annual Compensation: $203.8K
Vice President of Operations
Total Annual Compensation: $243.6K
Chief Medical Officer
Total Annual Compensation: $83.3K
Vice President of Quality Assurance
Total Annual Compensation: $246.5K
Compensation as of Fiscal Year 2016.
BioCardia, Inc. Key Developments
BioCardia, Inc., Annual General Meeting, Jun 15, 2017
Apr 28 17
BioCardia, Inc., Annual General Meeting, Jun 15, 2017, at 09:00 Pacific Standard Time. Location: Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road Palo Alto, CA 94304-1050 United States Agenda: To elect two Class I directors to serve until the 2020 annual meeting of stockholders and until their successors are duly elected and qualified; to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017; to hold a non-binding vote on executive compensation; to hold a non-binding vote on the frequency of executive compensation votes; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
BioCardia, Inc. Presents at ARM's 5th Annual Cell & Gene Therapy Investor Day, Apr-27-2017 11:25 AM
Apr 6 17
BioCardia, Inc. Presents at ARM's 5th Annual Cell & Gene Therapy Investor Day, Apr-27-2017 11:25 AM. Venue: The State Room, 60 State St., Boston, MA 02109, United States. Speakers: Peter A. Altman, Chief Executive Officer, President and Director.
Biocardia, Inc. Announces CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers
Dec 29 16
BioCardia, Inc. announced the initiation of the CardiAMP Heart Failure pivotal trial, a randomized, controlled, multi-center study of up to 260 patients evaluating CardiAMP cell therapy at up to 40 clinical sites in the United States. The trial has been initiated at two world-class centers: Johns Hopkins University, under the leadership of Dr. Peter Johnston and Dr. Gary Gerstenblith, and the University of Florida at Gainesville, under the leadership of Dr. David Anderson and Dr. Carl Pepine. The CardiAMP Therapy for heart failure integrates a biomarker panel, a cell processing system for autologous bone marrow-derived cells, and a unique transendocardial delivery system. This therapy will be reviewed under the PMA regulations by the FDA’s Center for Biologics Evaluation and Research (CBER) division.
Similar Private Companies By Industry
Recent Private Companies Transactions